Scarica l'app Stockscreener
2.53
5.86%
0.14
Dopo l'orario di chiusura:
2.77
0.24
+9.49%
Precedente Chiudi:
$2.39
Aprire:
$2.41
Volume 24 ore:
305.11K
Relative Volume:
1.06
Capitalizzazione di mercato:
$49.34M
Reddito:
-
Utile/perdita netta:
$-30.15M
Rapporto P/E:
-0.6325
EPS:
-4
Flusso di cassa netto:
$-21.66M
1 W Prestazione:
+3.05%
1M Prestazione:
-21.18%
6M Prestazione:
-13.95%
1 anno Prestazione:
+33.15%
Intervallo 1D:
$2.35
$2.55
Intervallo di 1 settimana:
$2.3001
$2.68
Portata 52W:
$1.10
$6.01
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Nome
Nrx Pharmaceuticals Inc
Settore
Industria
Telefono
484-254-6134
Indirizzo
1201 ORANGE STREET, WILMINGTON
Confronta NRXP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
2.53 | 46.61M | 0 | -30.15M | -21.66M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Nrx Pharmaceuticals Inc Stock (NRXP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-02 | Iniziato | BTIG Research | Buy |
Nrx Pharmaceuticals Inc Borsa (NRXP) Ultime notizie
NRx Pharmaceuticals: Navigating Regulatory Hurdles and Earnings Delays in the Race for Mental Health Breakthroughs - AInvest
NRx Pharmaceuticals Reschedules Q2 Earnings Call, Cites Need for Additional Financial Data Review - Stock Titan
NRx Pharmaceuticals (NASDAQ: NRXP) Petitions FDA to Ban Benzethonium Chloride From Ketamine Products - Yahoo Finance
NRx Pharmaceuticals: A Biotech Company Making Waves with Suicidal Depression Therapies and Clinics - AInvest
NRx Pharmaceuticals to Report Q2 2025 Financial Results on August 14, 2025 - AInvest
From Novel Therapies To Treat Suicidal Bipolar Depression To Launching A Network Of Clinics, NRx Pharmaceuticals Is Getting Attention On Wall Street | FinancialContent - FinancialContent
NRx Pharmaceuticals shares fall 5.86% premarket after FDA granted Fast Track designation to NRX-100 for suicidal ideation treatment. - AInvest
Why NRx Pharmaceuticals Inc. stock attracts strong analyst attentionFree Investment Webinars - thegnnews.com
NRx Pharmaceuticals (NASDAQ: NRXP) CEO to Join Fireside Chat at BTIG Virtual Biotechnology Conference - Yahoo Finance
NRx Pharmaceuticals shares rise 2.59% premarket after receiving final clearance for Dura Medical acquisition. - AInvest
New to The Street Show #682 Premieres on Bloomberg Tonight Featuring Industry Leaders: DataVault, PetVivo, Health In Tech, FLOKI, and NRx Pharma Backed by National TV Commercials and Outdoor Campaigns Sponsored by MUSQ, ArriveAI, and Sustai - Newport Daily News
Is NRx Pharmaceuticals Inc. Equity Warrant stock a value trapChannel Breakout Watchlist - newsyoung.net
Why Small-Cap Biotech NRx Pharmaceuticals Is Drawing Heavy Retail Buzz - Stocktwits
FDA Grants NRX-100 Fast Track Designation for Suicidal Ideation - HCPLive
$3 Billion Suicidal Depression Market May Soon be Accessible via - openPR.com
$3 Billion Suicidal Depression Market May Soon be Accessible via FDA Fast Track Designation for Effective NRX 100 Drug Therapy: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - Barchart.com
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025 - GlobeNewswire
NRx Pharmaceuticals (NASDAQ: NRXP) Receives FDA Fast Track Designation for NRX-100 in Treating Suicidal Ideation in Depression - TipRanks
NRx Pharmaceuticals stock price target raised to $21 by BTIG on FDA progress - Investing.com India
FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients With Depression, Including Bipolar Depression - Psychiatric Times
FDA grants fast track designation for NRx’s depression treatment By Investing.com - Investing.com Australia
New to The Street Client NRx Pharmaceuticals (NASDAQ:NRXP) Secures FDA Fast Track Designation for NRX-100, Expanding Reach to 13 Million Americans Confronting Suicidal Ideation - ACCESS Newswire
Nrx Pharmaceuticals shares rise 3.17% premarket after FDA granted designation for NRX-100, expanding addressable population. - AInvest
NRx Pharma Receives FDA Fast Track Designation for NRX-100 for Treating Suicidal Ideation in Depression - AInvest
FDA grants fast track designation to NRx for suicidal ideation drug - Investing.com Canada
NRX Pharmaceuticals: D. Boral Capital maintains Buy, PT raised to $31. - AInvest
NRx Pharmaceuticals and the Regulatory Catalysts Reshaping Mental Health Innovation - AInvest
FDA grants NRX-100 "unmet need" designation for treating 13 million Americans with suicidal thoughts. - AInvest
NRx Pharmaceuticals Receives FDA Fast Track Designation for NRX-100 in Treating Suicidal Ideation in Depression Patients - AInvest
FDA Fast Track Breakthrough: NRX-100 Shows 63% Success Rate in Suicidal Depression Treatment - Stock Titan
NRX Pharmaceuticals WRT NRXPW 2025Q2 Earnings Preview Upside Potential on New Product Launch - AInvest
NRX Pharmaceuticals NRXP 2025Q2 Earnings Preview Upside Potential Driven by New Product Launch - AInvest
Is a relief rally coming for NRx Pharmaceuticals Inc. Equity Warrant holdersSmart Stock Forecast Using AI Algorithms - Newser
NRx Pharmaceuticals Inc. stock trend outlook and recovery pathReal Chart Based Opportunity Identification - Newser
Using R and stats models for NRx Pharmaceuticals Inc. forecastingFree Breakout Confirmation With Entry Tracker - Newser
How to recover losses in NRx Pharmaceuticals Inc. Equity Warrant stockAI Stock Movement Forecast with Accuracy - Newser
Can machine learning forecast NRx Pharmaceuticals Inc. recoveryShort-Term Price Breakout Signal Analysis - Newser
Key metrics from NRx Pharmaceuticals Inc.’s quarterly dataPredictable Return Strategy with AI Support - Newser
Combining machine learning predictions for NRx Pharmaceuticals Inc. Equity WarrantGrowth Watchlist for Long Term Positioning - Newser
What machine learning models say about NRx Pharmaceuticals Inc. Equity WarrantFree Smart Trend Trading with Weekly Signals - Newser
Is NRx Pharmaceuticals Inc. stock bottoming outFree Risk Controlled Short Term Trade Plans - Newser
Relative strength of NRx Pharmaceuticals Inc. Equity Warrant in sector analysisTechnical Safety Zone Pattern Recognition - Newser
Bloomberg to Air New to The Street Episode #683 Featuring BioVie, FLOKI, PetVivo, and NRx Pharmaceuticals - AInvest
New to The Street to Air Show #683 on Bloomberg, Featuring BioVie, FLOKI, PetVivo, and NRx Pharmaceuticals - ACCESS Newswire
NRx Pharmaceuticals Clears Acquisition of Dura Medical, Expected to be Accretive to Revenue and EBITDA - AInvest
New Product Launches: Will They Boost NRx Pharmaceuticals Inc. Equity Warrant Stock in 2025Capital Safe Picks with Consistent Gains - Newser
Key resistance and support levels for NRx Pharmaceuticals Inc. Equity WarrantBuy Entry Confirmation Based on Technical Analysis - Newser
Trend analysis for NRx Pharmaceuticals Inc. this weekGrowth Summary Based on Market Positioning - Newser
Can NRx Pharmaceuticals Inc. recover in the next quarterTechnical Insight Guide for Safer Trades - Newser
Multi factor analysis applied to NRx Pharmaceuticals Inc. Equity WarrantBuy Point Strategy with Profit Protection - Newser
Is NRx Pharmaceuticals Inc. showing signs of accumulationFast Movement Forecast for Trading Success - Newser
Nrx Pharmaceuticals Inc Azioni (NRXP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):